Therapy Areas: Oncology
Sengenics Broadens Its Systems Serology Tools to Enable the Detection of a Wider Range of Autoantibody Biomarkers
2 December 2022 - - US-based precision medicine company Sengenics has launched Dual-Color IgG/IgA Assay Services, the company said.

The new Dual-Color Assays accelerate the pace and expand the biological space in the quest to discover new autoantibody biomarkers.

The Dual-Color IgG/IgA Assays enable the simultaneous and sensitive detection of IgG and IgA autoantibodies with exquisite specificity from very low sample volume input.

Dual-Color Assays Services are now available with all Sengenics protein arrays, which are based on the patented KREX protein folding technology and are designed for highly specific and reproducible discovery of autoantibody biomarkers.

The Dual-Color Assays are powered by expert bioinformatic and machine learning-based data analysis services, leading to the identification of biomarker signatures.

The new Dual-Color Assay Services expand the view of disease biology and accelerate autoantibody biomarker discovery across the autoimmune disease, immuno-oncology and neuroinflammation fields.

The Dual Color IgG/IgA Assay Services expands Sengenics' systems serology tools enabling a deeper dive into the humoral immune response.

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making.

Its solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.